Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
- 1 April 2001
- journal article
- review article
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 37 (4) , 677-688
- https://doi.org/10.1016/s0272-6386(01)80115-3
Abstract
No abstract availableKeywords
This publication has 53 references indexed in Scilit:
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999
- Vascular Aldosterone in Genetically Hypertensive RatsHypertension, 1997
- Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery diseaseThe American Journal of Cardiology, 1995
- Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 βEuropean Journal of Pharmacology: Molecular Pharmacology, 1995
- Left Ventricular Fibrosis in Renovascular Hypertensive RatsHypertension, 1995
- Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses.Hypertension, 1992
- Diabetes mellitus and hypertension.Hypertension, 1992
- Antialdosterones: Incidence and prevention of sexual side effectsJournal of Steroid Biochemistry, 1989
- Efficacy and tolerance of spironolactone in essential hypertensionThe American Journal of Cardiology, 1987
- Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscleLife Sciences, 1982